Tyrosine kinase inhibitorFDA-approvedFirst-line
Brafiib
Generic name: dabrafenib
How it works
Blocks the BRAF V600E mutation in cancer cells, preventing uncontrolled cell growth.
Cancer types
Melanoma— BRAF V600E-positive
Efficacy
In clinical trials, dabrafenib improved response rates in patients with BRAF V600E-positive melanoma, with a response rate of approximately 58%.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.